One of the main worries of Tel Aviv Stock Exchange (TASE) leaders recently has been the expected delisting of Perrigo Company (NYSE:PRGO; TASE:PRGO), if and when the company’s acquisition by Mylan Pharmaceuticals is completed.
Perrigo has been listed on the TASE for a decade (since it acquired Israeli company Agis), and it constitutes a considerable part of the Tel Aviv 25 index, in addition to being listed on the New York Stock Exchange. With a $27.6 billion market cap, Perrigo accounts for 9.8% of the index, putting it in third place behind Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Bank Leumi (TASE: LUMI).
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
The acquisition of the company and the delisting of its share are liable to significantly shrink trading volumes on the TASE, which in any case has been rather moribund in recent years…
Published by Globes [online], Israel business news – www.globes-online.com
Three Way Takeover Battle: Teva Doesn’t Take NO as an Answer
Teva Pharmaceutical Industries Ltd, an Israeli-based company, has acquired a 1.35 percent stake in Mylan through purchases on the open market, increasing pressure on its rival’s management to come to the More…
Three Way Takeover Battle: Mylan Mulling Improved Offer for Perrigo – Bloomberg
Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: More…
Perrigo Backs Reason to Spurn Mylan
When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a different company, according to its CEO Joe Papa. Back More…
Perrigo Again Rejects Improved Mylan Offer
Mylan offered Perrigo shareholders $75 plus 2.3 Mylan shares per Perrigo share, for a total of $35.6 billion. Perrigo Company (NYSE:PRGO; TASE:PRGO) board of directors has rejected Mylan’s improved offer. Mylan More…
Mylan Raises Offer to Buy Perrigo to $35.6 Billion
Mylan, itself the subject of a hostile takeover bid from Teva, is raising its offer for Perrigo for the second time. Mylan N.V. has for the second time raised its offer to buy US-Irish-Israeli generic pharmaceuticals More…
